Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 15/20 | 0.44 |
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227314 | 0.86 | TDP1 (0.45) | TDP1C5AR1GNRHRTNKSCYP2C9 | |
| SCHEMBL25431431 | 0.81 | TP53 (0.47) | TDP1C5AR1TNKSCYP2C9CYP2C19 | |
| SCHEMBL30482287 | 0.77 | LMNA (0.46) | TDP1C5AR1TNKSCYP2C9CYP2C19 | |
| SCHEMBL30482353 | 0.76 | GNRHR (0.43) | TDP1C5AR1GNRHR | |
| SCHEMBL30482281 | 0.75 | TDP1 (0.40) | TDP1C5AR1GNRHRTNKSCYP2C9 | |
| SCHEMBL26228669 | 0.72 | HSD17B13 (0.68) | — | |
| SCHEMBL30482352 | 0.71 | TSHR (0.55) | TDP1C5AR1 | |
| SCHEMBL24247609 | 0.68 | TSHR (0.59) | TDP1 | |
| SCHEMBL31227182 | 0.67 | TSHR (0.41) | TDP1C5AR1GNRHR | |
| SCHEMBL22613010 | 0.67 | C5AR1 (0.53) | TDP1C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100993-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4469451-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | Inipharm, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119032090-A | 2-Substituted thiazole HSD17B13 inhibitors and uses thereof | 伊尼制药公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2023146897-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100993-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | TDP1 1273/4885C5AR1 4830/4885GNRHR 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.